Results for tag: "Biricodar"

Biricodar (VX-702) is a small molecule inhibitor of the breast cancer resistance protein (BCRP) used in the treatment of oncology drugs. It is a potent inhibitor of BCRP, a transporter protein that is overexpressed in many types of cancer cells and is involved in the efflux of chemotherapeutic agents. Biricodar has been studied in combination with chemotherapy agents such as paclitaxel, doxorubicin, and topotecan, and has been shown to increase the efficacy of these agents in preclinical models. Biricodar is currently in Phase III clinical trials for the treatment of metastatic breast cancer and is being developed by Vertex Pharmaceuticals. Other companies involved in the development of BCRP inhibitors for oncology drugs include Novartis, AstraZeneca, and GlaxoSmithKline. Additionally, several biotechnology companies are developing BCRP inhibitors for the treatment of various types of cancer, including Celleron Therapeutics, OncoSynergy, and OncoMed Pharmaceuticals. Show Less Read more